Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 8/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | CCR4 | P51679 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.31 |
| ▸ | CMA1 | P23946 | 1/20 | 0.31 |
| ▸ | F7 | P08709 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | F3 | P13726 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3840439 | 0.74 | CYP1A2 (0.36) | EGFRFLT1PARP1CYP2A6 | |
| SCHEMBL1160240 | 0.73 | PARP1 (0.40) | AHRPARP1CCR4TRPA1CA1 | |
| SCHEMBL29733471 | 0.73 | CYP2A6 (0.41) | CYP2A6 | |
| SCHEMBL2368459 | 0.73 | CYP2A6 (0.41) | CYP2A6 | |
| SCHEMBL4419238 | 0.71 | TNF (0.39) | EGFRFLT1AHRCYP2A6 | |
| SCHEMBL19206984 | 0.71 | CYP2A6 (0.40) | CYP2A6 | |
| SCHEMBL12279072 | 0.71 | CYP2A6 (0.40) | CYP2A6 | |
| SCHEMBL793638 | 0.69 | CYP2A6 (0.46) | PARP1CYP2A6 | |
| SCHEMBL2398840 | 0.69 | AHR (0.52) | AHRPARP1CYP2A6NR4A2F7 | |
| SCHEMBL29913244 | 0.69 | AHR (0.36) | AHRPARP1GAARHEB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| EP-4041238-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| EP-3049420-B1 | THIENO[2,3-E]INDOLE DERIVATIVES AS NEW ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2019-05-15 | — | — | EP | disclosed |
| US-10266547-B2 | Thieno[2,3-e]indole derivatives as new antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-04-23 | — | — | US | disclosed |
| US-10266547-B2 | Thieno[2,3-e]indole derivatives as new antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-04-23 | — | — | US | disclosed |
| US-10266547-B2 | Thieno[2,3-e]indole derivatives as new antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-04-23 | — | — | US | disclosed |
| US-20160229867-A1 | THIENO[2,3-e]INDOLE DERIVATIVES AS NEW ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-08-11 | — | — | US | disclosed |
| US-20160229867-A1 | THIENO[2,3-e]INDOLE DERIVATIVES AS NEW ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-08-11 | — | — | US | disclosed |
| EP-3049420-A1 | THIENO[2,3-e]INDOLE DERIVATIVES AS NEW ANTITUMOR AGENTS | Nerviano Medical Sciences S.r.l. (IT) | 2016-08-03 | — | — | EP | disclosed |
| EP-3049420-A1 | THIENO[2,3-e]INDOLE DERIVATIVES AS NEW ANTITUMOR AGENTS | Nerviano Medical Sciences S.r.l. (IT) | 2016-08-03 | — | — | EP | disclosed |
| WO-2015044003-A1 | THIENO[2,3-e]INDOLE DERIVATIVES AS NEW ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015044003-A1 | THIENO[2,3-e]INDOLE DERIVATIVES AS NEW ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266547-B2 | Thieno[2,3-e]indole derivatives as new antitumor agents | INMT, TOP2A, TOP1 | EGFR 589/4885FLT1 3569/4885AHR 721/4885 |
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | EGFR 458/4885FLT1 757/4885AHR 962/4885 |
| US-20160229867-A1 | THIENO[2,3-e]INDOLE DERIVATIVES AS NEW ANTITUMOR AGENTS | INMT, TOP2A, TOP1 | EGFR 589/4885FLT1 3569/4885AHR 721/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | EGFR 1813/4885FLT1 1011/4885AHR 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.